Neuberger Berman Group LLC has opened a new $40.8M position in $CDTX, per a new SEC 13F filing. This disclosure reflects the funds' holdings for the 12-31-2025 report period. You can see the fund's full portfolio on Quiver Quantitative, and also track the largest institutional owners of $CDTX.
$CDTX Hedge Fund Activity
We have seen 155 institutional investors add shares of $CDTX stock to their portfolio, and 73 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TCG CROSSOVER MANAGEMENT, LLC removed 1,005,901 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $96,325,079
- PARADIGM BIOCAPITAL ADVISORS LP added 961,164 shares (+inf%) to their portfolio in Q3 2025, for an estimated $92,041,064
- VANGUARD GROUP INC added 776,527 shares (+63.1%) to their portfolio in Q4 2025, for an estimated $171,527,049
- FMR LLC added 666,815 shares (+613.3%) to their portfolio in Q3 2025, for an estimated $63,854,204
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 650,000 shares (-59.1%) from their portfolio in Q3 2025, for an estimated $62,244,000
- BVF INC/IL added 627,773 shares (+79.8%) to their portfolio in Q3 2025, for an estimated $60,115,542
- UBS GROUP AG added 601,370 shares (+127.0%) to their portfolio in Q4 2025, for an estimated $132,836,619
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CDTX Insider Trading Activity
$CDTX insiders have traded $CDTX stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $CDTX stock by insiders over the last 6 months:
- SHANE WARD (COO & CLO) sold 9,959 shares for an estimated $2,191,746
- NICOLE NEGAR DAVARPANAH (Chief Medical Officer) sold 474 shares for an estimated $29,796
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CDTX Analyst Ratings
Wall Street analysts have issued reports on $CDTX in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 11/07/2025
- Morgan Stanley issued a "Overweight" rating on 10/16/2025
- JP Morgan issued a "Overweight" rating on 10/10/2025
- WBB Securities issued a "Strong Buy" rating on 10/09/2025
- JMP Securities issued a "Market Outperform" rating on 10/03/2025
To track analyst ratings and price targets for $CDTX, check out Quiver Quantitative's $CDTX forecast page.
$CDTX Price Targets
Multiple analysts have issued price targets for $CDTX recently. We have seen 8 analysts offer price targets for $CDTX in the last 6 months, with a median target of $170.0.
Here are some recent targets:
- Joseph Stringer from Needham set a target price of $135.0 on 11/07/2025
- Brian Abrahams from RBC Capital set a target price of $145.0 on 11/07/2025
- Sara Nik from HC Wainwright & Co. set a target price of $150.0 on 10/21/2025
- Maxwell Skor from Morgan Stanley set a target price of $190.0 on 10/16/2025
- Anupam Rama from JP Morgan set a target price of $200.0 on 10/10/2025
- Steve Brozak from WBB Securities set a target price of $199.0 on 10/09/2025
- Roy Buchanan from JMP Securities set a target price of $173.0 on 10/03/2025
Note that there may be inaccuracies in these estimates due to filing errors by the funds, parsing errors by us, or other anomalies.
Check out Quiver Quantitative's $CDTX ticker page for more data.
